GlassScriptPhysician profile
Preeti Gupta
NPI 1023135720
$4,801.49
in general payments reported to CMS, 2019-2025
30 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $291 · 2021: $721 · 2022: $502 · 2023: $710 · 2024: $746 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,998 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,997.66 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $898.76 | 2021-2024 | Xcopri |
| Ucb, INC. | $579.08 | 2019-2025 | Fintepla, Nayzilam, Briviact |
| Abbvie INC. | $474.84 | 2021-2025 | |
| Livanova USA, INC. | $403.62 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Neurelis, INC. | $381.84 | 2024-2025 | Valtoco |
| Emd Serono, INC. | $325.87 | 2025 | |
| Sunovion Pharmaceuticals INC. | $245.61 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $172.92 | 2019-2025 | |
| Lundbeck LLC | $156.09 | 2021-2024 | Vyepti |
| Pfizer INC. | $132.52 | 2022-2025 | |
| Kyowa Kirin, INC. | $119.52 | 2025 | |
| Eisai INC. | $104.89 | 2019-2025 | |
| Biogen, INC. | $100.11 | 2019-2023 | |
| Allergan, INC. | $77.75 | 2020-2021 | |
| Neuropace, INC. | $77.69 | 2022-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $76.29 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $61.30 | 2019-2023 | |
| Mdd US Operations, LLC | $48.46 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $45.85 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $40.82 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $39.50 | 2023-2024 | Fycompa |
| Amgen INC. | $37.10 | 2019 | |
| Medtronic, INC. | $36.40 | 2023 | Intellis Adaptivestim |
| Csl Behring | $31.76 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $28.20 | 2021 | |
| Greenwich Biosciences, INC. | $27.89 | 2020 | |
| Celgene Corporation | $27.26 | 2021 | |
| Impel Pharmaceuticals INC. | $20.91 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.95 | 2021 | |
| Medtronic USA, INC. | $12.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preeti Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.